文献速递类风湿关节炎

ABBV-154治疗活动性类风湿关节炎的疗效与安全性:一项2b期随机安慰剂对照试验

Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled Trial.
PubMed 文献 · Arthritis Rheumatol · 2025-09-01

这项2b期随机安慰剂对照试验评估了抗体药物偶联物ABBV-154在背景甲氨蝶呤治疗下、对至少一种既往b/tsDMARD应答不足的中重度活动性类风湿关节炎患者的疗效与安全性;共治疗472例患者,第12周ABBV-154各剂量组ACR50应答率(25.5%-44.4%)高于安慰剂组(6.3%,所有P<0.001),所有ABBV-154剂量组至第12周的治疗中出现的不良事件发生率与安慰剂相似;ABBV-154的临床开发已终止,研究提前结束。

要点

  • 第12周ABBV-154各剂量组ACR50应答率为25.5%-44.4%,安慰剂组为6.3%(所有P<0.001)。
  • 所有ABBV-154治疗组ACR20应答率均高于安慰剂组(P<0.001)。
  • 所有ABBV-154剂量组至第12周的治疗中出现的不良事件发生率与安慰剂相似,ABBV-154组发生10例严重感染治疗中出现的不良事件。

核心结论

  • 在既往b/tsDMARD应答不足的类风湿关节炎患者中,ABBV-154较安慰剂显示出更优疗效。
  • 所有ABBV-154治疗组的治疗中出现的不良事件发生率与安慰剂相当。
  • 这些发现为类风湿关节炎新型抗体药物偶联物的设计提供了有用信息。

研究设计与样本

  • 2b期随机、安慰剂对照试验,患者按1:1:1:1:1随机分配至皮下注射ABBV-154 40 mg、150 mg或340 mg每2周一次,340 mg每4周一次,或安慰剂。
  • 纳入中重度活动性类风湿关节炎患者,背景甲氨蝶呤治疗,且对至少一种既往b/tsDMARD应答不足。
  • 共治疗472例患者;主要终点为第12周达到美国风湿病学会50%改善标准(ACR50)应答。
  • ABBV-154的临床开发已终止,研究提前结束。

主要发现

  • 第12周ABBV-154各剂量组ACR50应答率为25.5%-44.4%,安慰剂组为6.3%(所有P<0.001)。
  • 所有ABBV-154治疗组ACR20应答率均高于安慰剂组(P<0.001)。
  • 大多数ABBV-154组达到了其他次要终点。
  • 所有ABBV-154剂量组至第12周的治疗中出现的不良事件发生率与安慰剂相似。
  • ABBV-154组发生10例严重感染治疗中出现的不良事件。

局限性

  • ABBV-154的临床开发已终止,研究提前结束。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite the availability of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks. ABBV-154, an antibody-drug conjugate, is made up of adalimumab linked to a glucocorticoid receptor modulator. This phase 2b study evaluated the efficacy and safety of ABBV-154 in patients with moderately to severely active RA receiving background methotrexate with inadequate response to at least one prior b/tsDMARD. METHODS: Patients were randomized 1:1:1:1:1 to subcutaneous ABBV-154 40, 150, or 340 mg every other week; 340 mg every 4 weeks; or placebo. The primary endpoint was achieving 50% improvement in the American College of Rheumatology response criteria (ACR50) at week 12; secondary endpoints included achieving the ACR20 and ACR70 criteria. Treatment-emergent adverse events (TEAEs) were monitored. Clinical development of ABBV-154 was discontinued; the study was terminated early. RESULTS: Overall, 472 patients were treated. At week 12, more patients achieved ACR50 (primary endpoint) with ABBV-154 (25.5%-44.4% across dose groups) versus placebo (6.3%; all P < 0.001). ACR20 response rates were higher in all ABBV-154 treatment groups versus placebo (P < 0.001). Most ABBV-154 groups achieved the other secondary endpoints. For all ABBV-154 doses, TEAEs rates through week 12 were similar to placebo. Ten serious infection TEAEs occurred in the ABBV-154 groups. CONCLUSION: ABBV-154 demonstrated superior efficacy over placebo in patients with RA and inadequate response to prior b/tsDMARDs. TEAE rates in all ABBV-154 arms were comparable with placebo. These findings provide useful insights into the design of new antibody-drug conjugates for RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Buttgereit F, Singhal A, Kivitz A, et al. Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2025. PMID: 40495262. doi:10.1002/art.43266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。